Meet the Network and Community Leadership
Network: Development, Regulatory, & Outcomes (DRO)
Community: Early Development & Drug Safety (EDDS)

Community Chair:
Clapton Dias, BPharm, PhD
BioMarin Pharmaceutical Inc.

Clapton Dias, BPharm., Ph.D. joined BioMarin Pharmaceutical Inc. in 2015 to lead Clinical Pharmacology which encompasses Nonclinical PK/PD, DMPK, Clinical PK/PD and Pharmacometrics for R&D pipeline and marketed products. Dr. Dias's career has spanned different biopharmaceutical companies (Johnson &Johnson, Amgen and Bristol Myers Squibb) across the Cardiovascular, Metabolics, Neuroscience and Immunology therapeutic areas. At J&J, he was Scientific Director and Clinical Pharmacology Leader for the Metabolics (Type 2 Diabetes) portfolio supporting life cycle management activities for Invokana® and contributing to development of early pipeline molecules. Prior to J&J, he spent several years at Amgen as Director of Clinical Pharmacology & Early Development where he represented Clinical Pharmacology and Early Development on development teams for a variety of biologic and small molecule programs. In addition to his Clinical Pharmacology responsibilities, he was also the Early Development Leader (EDL) for several molecules in Amgen's pipeline. In this capacity, he provided leadership to both the Core Strategy team and the Global Development Team. Notably, Dr. Dias was the EDL for Repatha®; Amgen's anti-PCSK9 monoclonal antibody for hypercholesterolemia. At Bristol Myers Squibb, Dr. Dias contributed to the development of Eliquis® and its back-up molecules by designing and executing key classical clinical pharmacology studies. Currently, as Head of Clinical Pharmacology, Dr. Dias is a member of leadership teams that shape development of molecules in genetically defined rare diseases. Dr. Dias received his interdisciplinary Ph.D. in Pharmaceutical Sciences from the University of Missouri-Kansas City and a Bachelor's degree in Pharmacy from the University of Bombay, India.